Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: A general overview

P. Viola, V. Testa, L. Ferro Desideri, L. Di Cello, C. Rutigliani, A. Vagge, M. Nicolò, R. Cian, C. E. Traverso

Research output: Contribution to journalReview articlepeer-review


Anti-vascular endothelial growth factors currently are the first-line treatment option for neovascular age-related macular degeneration (nAMD) and other retinal vascular disorders, and their clinical use is associated with high financial burden. Biosimilars are a type of biological product highly similar to referral biologic drugs; they are increasing competition among biologics and have the potential to reduce the overall expenditures on biologics. In this comprehensive literature review, the current investigational biosimilars acting on retinal diseases are discussed. The authors review the results of clinical studies and highlight ongoing trials. Several biosimilar candidates are under evaluation and the pipeline will rapidly change in the future, as soon as each patent expires. Clinicians have to know these new therapeutic agents, which might come in the mainstream clinical practice as a more cost-efficient option.

Original languageEnglish
Pages (from-to)689-697
Number of pages9
JournalDrugs of Today
Issue number11
Publication statusPublished - Nov 2021


  • Aflibercept
  • Anti-vascular endothelial growth factor (VEGF) drugs
  • Bevacizumab
  • Biosimilars
  • Intravitreal injections
  • Macular degeneration
  • Ranibizumab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: A general overview'. Together they form a unique fingerprint.

Cite this